Biopharma manufacturing intelligence

The foreknowing layer for every batch.

Every bioreactor. Every fill-finish line. One interpreted operating state. One early warning — hours before the deviation is obvious. Insight-only. Validation-ready.

Request a demo See the architecture

The problem

Your site runs historians, MES, LIMS, and PAT tools. And a process engineer reconciling signals manually — after the deviation report is already written, after the batch is already lost. The point tools work. The foreknowledge between them doesn't.

The Praescia difference

Praescia is the layer that sits above the point tools you already own. It reads what historians, in-line sensors, and MES produce. It maintains a live state of each batch run against the golden trajectory. And when it detects the onset of a deviation — the early metabolic drift, the DO deflection, the titer shortfall forming — it tells you, with the reason, while there is still time to act.

Not another dashboard. The substrate.

What it catches — every run, in the background

Hours–days ahead

Golden-batch deviation onset

A live run departing its golden trajectory. Named, explained, and surfaced while intervention is still possible.

Pre-harvest

Early titer / yield / OOS-risk signal

A predicted titer or yield shortfall — called before the release assay, not by it.

Real-time

Fill-finish line bottleneck onset

Constraint transition and throughput-loss risk on the fill-finish or drug-product line.

Continuous

Cleanroom / utility excursion

Environmental monitoring, WFI, HVAC, and equipment operating-state drift — caught before a batch-record event.

On transfer

Tech transfer drift

A new site or scale deviating from the reference process — detected as the first runs land, not at tech transfer review.

In-transit

Cold-chain excursion risk

Material and sample logistics excursion risk — surfaced before the shipment arrives out-of-spec.

Pre-release

Batch-record integrity flag

Data integrity signals (ALCOA+) in the in-flight batch record — caught before release, not in an audit.

At density

Cross-site performance gap

Fleet-level benchmarking that only exists once the network has density. A premium tier that compounds as sites grow.

The background sentinel. Silent by design. Speaks only when it must.

The three invariants

Every claim Praescia makes reinforces three architectural commitments. They hold at every layer, in every deployment, for every customer.

Insight-only

Praescia observes, predicts, and advises. It never touches the process equipment. Permanent — not a phase, not a configuration, not a workaround for regulators.

Validation-ready by design

21 CFR Part 11 · EU Annex 11 · GAMP 5 · ALCOA+ are built in, not bolted on. We lower your computer-system validation burden — we don’t add to it.

Explainable, not a black box

Every advisory carries named drivers and a reason code. Defensible to a process engineer, to QA, and to a regulatory reviewer. No opaque model conclusions.

How it plugs in

Standards on one side. Biopharma-vendor connectors on the other. One appliance in your tenant, your on-premises DMZ, or your air-gap.

Standards-based

OPC-UA · MQTT · REST · SFTP · syslog · mTLS · SAML 2.0 · SCIM 2.0

Drops into your IT and OT posture without demanding architectural change.

Biopharma connectors

OSIsoft PI · Honeywell PHD · Rockwell FactoryTalk · Werum PAS-X · LabVantage · STARLIMS · Benchling · Veeva Vault · METTLER TOLEDO · Siemens SIMATIC IT

Every new source is a plugin. Not a fork.

Design-partner program

Praescia is entering its design-partner phase — working with CDMOs and biotech MSAT teams with real batch data to prove detection and refine the model. If you have a bioreactor or fill-finish line and a pain we described above, we want to talk.

Apply for the design-partner program